Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EarkartBOM:544549 19 ROE % is 14.62% as of Mar. 2026, which is 37% below its 10-year median of 23.12. GuruFocus rates BOM:544549 with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Earkart ranks better than 65.33% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Earkart's annualized net income for the quarter that ended in Mar. 2026 was ₹61.6 Mil. Earkart's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹421.3 Mil. Therefore, Earkart's annualized ROE % for the quarter that ended in Mar. 2026 was 14.62%.
The historical rank and industry rank for Earkart's ROE % or its related term are showing as below:
BOM:544549'
s ROE % Range Over the Past 10 Years
Min: 2.21 Med: 23.12 Max: 41.77
Current: 7.31
During the past 5 years, Earkart's highest ROE % was 41.77%. The lowest was 2.21%. And the median was 23.12%.
BOM:544549's ROE % is ranked better than 65.33% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.54
vs BOM:544549: 7.31
Earkart (BOM:544549) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Earkart ROE % Related Terms
Earkart ROE % Historical Data
* Premium members only.
The historical data trend for Earkart's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Earkart ROE % Chart
Earkart Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
ROE %
2.21
23.12
31.21
41.77
11.71
Earkart Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
ROE %
0.00
0.00
0.00
0.00
14.62
BOM:544549 vs ABT, SYK, MDT: ROE % Comparison
For the Medical Devices subindustry, Earkart's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earkart ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Earkart's ROE % distribution charts can be found below:
* The bar in red indicates where Earkart's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Earkart (BOM:544549) has a ROE % of 14.62% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Earkart and its competitors. This is 37% below median its historical median of 23.12. Over the past decade, Earkart's ROE % has ranged from 2.21 to 41.77. According to the industry distribution chart, Earkart ranks #277 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 34.7%.
Is Earkart's ROE % too high?
Earkart's current ROE % of 14.62% is 37% below median its 10-year median of 23.12. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 41.77. The Medical Devices & Instruments industry median ROE % is 2.54. Earkart's value of 14.62% is 475.6% above this industry median. Based on the distribution chart, Earkart ranks #277 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Earkart has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Earkart's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Earkart ranks #277 out of 799 companies for ROE %. This puts Earkart in the upper half of its industry. The industry median ROE % is 2.54. Earkart's value of 14.62% is 475.6% above this benchmark. Historically, Earkart's own ROE % has ranged from 2.21 to 41.77 over the past decade. While the company's 10-year median is 23.12 vs. the industry median of 2.54, Earkart has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earkart's current ROE % of 14.62% is 475.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Earkart and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earkart's current ROE % is 14.62%, which is 37% below median its own 10-year median of 23.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earkart stock overvalued right now?
Earkart (BOM:544549) has a current ROE % of 14.62%. The current ROE % is 14.62%, which is 37% below median its 10-year median of 23.12 and 475.6% above the Medical Devices & Instruments industry median of 2.54. Earkart's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Earkart (BOM:544549), the current ROE % is 14.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Earkart Ltd is a hearing care company based in India that manufactures and distributes modern hearing aids and related accessories at affordable prices. The company also trades in hearing aids and parts from both Indian and foreign brands. Earkart has expanded its product range to include mobility aids like adjustable foldable walkers and therapy kits for children with disabilities. It developed a remote audiometry machine operated by audiologists to facilitate hearing tests remotely, improving access to hearing care services across India. Earkart operates through a wide network of clinics and hearing solution dispensers, blending manufacturing with a customer-focused approach to reach underserved regions.
19GF Score
Get the complete analysis for BOM:544549
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544549 has been successfully added to your 
